journal article·2021-02-16Open access

Comparative Analysis of Cell-Free miR-205-5p, let-7f-5p, and miR-483-5p Expression in Ovarian Cell Cultures and Plasma Samples of Patients with Ovarian Cancer

Éva Márton, Alexandra Varga, Beáta Soltész, András Penyige, János Lukács, Róbert Póka, Bálint Nagy, Melinda Szilágyi

Applied Sciences· Volume 11· Issue 4

Abstract

The term liquid biopsy reveals a non-invasive diagnostic method that might be based on the quantification of cell-free microRNAs in body fluids. However, the identification of candidates for liquid biopsy is challenging. Our aim was to compare the cell-free expression of miR-483-5p, miR-205-5p, and let-7f-5p in ovarian cell cultures and plasma samples of patients with ovarian cancer. Both the intracellular and cell-free expression of miR-205-5p and let-7f-5p proved to be higher in the Estrogen Receptor α (ERα) expressing PEO1 cell-line than in the estrogen non-sensitive A2780. Moreover, the expression of let-7f-5p was up-regulated in response to estradiol exposure that was diminished after the addition of an ERα selective antagonist. MiR-483-5p had lower intracellular and cell-free expression in PEO1. All these miRNAs had detectable expression level in plasma samples, among which miR-205-5p proved to be overexpressed in the plasma samples of patients with ovarian tumors compared to healthy controls and possessed an acceptable diagnostic potential with ROC-AUC 0.683 (95% CI 0.57–0.795). Functional annotation clustering of the target genes of miR-205-5p revealed several clusters involved in cancer development. We suggest that miR-205-5p might be a promising biomarker candidate in ovarian cancer that should be further analyzed in larger sample size.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · Cancer-related molecular mechanisms research · Circular RNAs in diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Human Genetics, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary

Faculty of Pharmacy, University of Debrecen, H-4032 Debrecen, Hungary

Department of Obstetrics and Gynecology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary

Funding

New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund

References (47)

Show source-provided references
1. Szilágyi, M., Pös, O., Márton, É., Buglyó, G., Soltész, B., Keserű, J., Penyige, A., Szemes, T., and Nagy, B. (2020). Circulating Cell-Free Nucleic Acids: Main Characteristics and Clinical Application. Int. J. Mol. Sci., 21.10.3390/ijms21186827 ↗
2. Larrea, E., Sole, C., Manterola, L., Goicoechea, I., Armesto, M., Arestin, M., Caffarel, M.M., Araujo, A.M., Araiz, M., and Fernandez-Mercado, M. (2016). New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies. Int. J. Mol. Sci., 17.10.3390/ijms17050627 ↗
3. MicroRNAs in cancer: Biomarkers, functions and therapy10.1016/j.molmed.2014.06.005 ↗
4. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation10.3389/fendo.2018.00402 ↗
5. Cancer statistics, 201810.3322/caac.21442 ↗
6. Epidemiology of ovarian cancer: A review10.20892/j.issn.2095-3941.2016.0084 ↗
7. Circulating biomarkers in epithelial ovarian cancer diagnosis: From present to future perspective10.21037/atm.2017.05.13 ↗
8. Clinical use of cancer biomarkers in epithelial ovarian cancer: Updated guidelines from the European Group on Tumor Markers10.1097/IGC.0000000000000586 ↗
9. Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer10.1016/j.jbiotec.2019.04.003 ↗
10. Penyige, A., Márton, É., Soltész, B., Szilágyi-Bónizs, M., Póka, R., Lukács, J., Széles, L., and Nagy, B. (2019). Circulating miRNA profiling in plasma samples of ovarian cancer patients. Int. J. Mol. Sci., 20.10.3390/ijms20184533 ↗
11. Márton, É., Varga, A., Széles, L., Göczi, L., Penyige, A., Nagy, B., and Szilágyi, M. (2020). The Cell-Free Expression of MiR200 Family members correlates with estrogen sensitivity in human epithelial ovarian cells. Int. J. Mol. Sci., 21.10.3390/ijms21249725 ↗
12. (2021, January 20). miRTargetLink. Available online: https://ccb-web.cs.uni-saarland.de/mirtargetlink/multinet.php.
13. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists10.1093/nar/gkn923 ↗
14. Antagonists selective for estrogen receptor α10.1210/endo.143.3.8704 ↗
15. MiR-205 in cancer: An angel or a devil?10.1016/j.ejcb.2012.11.002 ↗
16. Chauhan, N., Dhasmana, A., Jaggi, M., Chauhan, S.C., and Yallapu, M.M. (2020). miR-205: A Potential biomedicine for cancer therapy. Cells, 9.10.3390/cells9091957 ↗
17. miR-200a/miR-141 and miR-205 upregulation might be associated with hormone receptor status and prognosis in endometrial carcinomas
18. Suppression of cell growth and invasion by miR-205 in breast cancer10.1038/cr.2009.18 ↗
19. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma10.1038/onc.2012.55 ↗
20. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma10.1200/JCO.2008.19.4134 ↗
21. Micro-RNA profiling in kidney and bladder cancers
22. Eyking, A., Reis, H., Frank, M., Gerken, G., Schmid, K.W., and Cario, E. (2016). MiR-205 and MiR-373 are associated with aggressive human mucinous colorectal cancer. PLoS ONE, 11.10.1371/journal.pone.0156871 ↗
23. Effect of miR‑205 on proliferation and migration of thyroid cancer cells by targeting CCNB2 and the mechanism
24. MicroRNA Signatures in Human Ovarian Cancer10.1158/0008-5472.CAN-07-1936 ↗
25. MicroRNA-205 promotes cell invasion by repressing TCF21 in human ovarian cancer10.1186/s13048-017-0328-1 ↗
26. Upregulation of MiR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression10.1038/srep41330 ↗
27. miR-205 regulates the proliferation and invasion of ovarian cancer cells via suppressing PTEN/SMAD4 expression
28. Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis10.7150/thno.37455 ↗
29. Zheng, H., Zhang, L., Zhao, Y., Yang, D., Song, F., Wen, Y., Hao, Q., Hu, Z., Zhang, W., and Chen, K. (2013). Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS ONE, 8.10.1371/journal.pone.0077853 ↗
30. miR-205 promotes tumor proliferation and invasion through targeting ESRRG in endometrial carcinoma10.3892/or.2013.2400 ↗
31. The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression10.1038/s41419-017-0102-8 ↗
32. The role of let-7 in cell differentiation and cancer10.1677/ERC-09-0184 ↗
33. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival10.1183/09031936.00029610 ↗
34. Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances10.7754/Clin.Lab.2013.130133 ↗
35. Liang, S., He, L., Zhao, X., Miao, Y., Gu, Y., Guo, C., Xue, Z., Dou, W., Hu, F., and Wu, K. (2011). MicroRNA Let-7f Inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS ONE, 6.10.1371/journal.pone.0018409 ↗
36. Let-7as biomarker, prognostic indicator, and therapy for precision medicine in cancer10.1186/s40169-019-0240-y ↗
37. Estradiol-regulated microRNAs control estradiol response in breast cancer cells10.1093/nar/gkp500 ↗
38. Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs10.3389/fimmu.2020.00151 ↗
39. miR–483-5p promotes prostate cancer cell proliferation and invasion by targeting RBM510.1590/s1677-5538.ibju.2016.0595 ↗
40. Identification of cell-free microRNAs in the urine of patients with prostate cancer10.1016/j.urolonc.2014.09.015 ↗
41. Upregulated miR-483-5p expression as a prognostic biomarker for esophageal squamous cell carcinoma10.3233/CBM-160506 ↗
42. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients10.1530/ERC-13-0051 ↗
43. Serum miR-483-5p: A novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma10.1007/s13277-015-3514-z ↗
44. Exploration of Genome-Wide Circulating MicroRNA in Hepatocellular Carcinoma: MiR-483-5p as a Potential Biomarker10.1158/1055-9965.EPI-13-0237 ↗
45. MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors10.1016/j.surg.2013.06.022 ↗
46. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma10.1007/s13277-013-0928-3 ↗
47. miR-483–5p and miR-486–5p are down-regulated in cumulus cells of metaphase II oocytes from women with polycystic ovary syndrome10.1016/j.rbmo.2015.06.023 ↗